技术资料
-
Jones KR and Reichardt LF (OCT 1990) Proceedings of the National Academy of Sciences of the United States of America 87 20 8060--4Molecular cloning of a human gene that is a member of the nerve growth factor family.
Cell death within the developing vertebrate nervous system is regulated in part by interactions between neurons and their innervation targets that are mediated by neurotrophic factors. These factors also appear to have a role in the maintenance of the adult nervous system. Two neurotrophic factors,nerve growth factor and brain-derived neurotrophic factor,share substantial amino acid sequence identity. We have used a screen that combines polymerase chain reaction amplification of genomic DNA and low-stringency hybridization with degenerate oligonucleotides to isolate human BDNF and a human gene,neurotrophin-3,that is closely related to both nerve growth factor and brain-derived neurotrophic factor. mRNA products of the brain-derived neurotrophic factor and neurotrophin-3 genes were detected in the adult human brain,suggesting that these proteins are involved in the maintenance of the adult nervous system. Neurotrophin-3 is also expected to function in embryonic neural development. View Publication -
Houng W-L et al. (JAN 2012) International journal of molecular sciences 13 3 3988--4002Dihydrolipoic acid induces cytotoxicity in mouse blastocysts through apoptosis processes.
α-Lipoic acid (LA) is a thiol with antioxidant properties that protects against oxidative stress-induced apoptosis. LA is absorbed from the diet,taken up by cells and tissues,and subsequently reduced to dihydrolipoic acid (DHLA). In view of the recent application of DHLA as a hydrophilic nanomaterial preparation,determination of its biosafety profile is essential. In the current study,we examined the cytotoxic effects of DHLA on mouse embryos at the blastocyst stage,subsequent embryonic attachment and outgrowth in vitro,in vivo implantation by embryo transfer,and early embryonic development in an animal model. Blastocysts treated with 50 μM DHLA exhibited significantly increased apoptosis and a corresponding decrease in total cell number. Notably,the implantation success rates of blastocysts pretreated with DHLA were lower than that of their control counterparts. Moreover,in vitro treatment with 50 μM DHLA was associated with increased resorption of post-implantation embryos and decreased fetal weight. Data obtained using an in vivo mouse model further disclosed that consumption of drinking water containing 100 μM DHLA led to decreased early embryo development,specifically,inhibition of development to the blastocyst stage. However,it appears that concentrations of DHLA lower than 50 μM do not exert a hazardous effect on embryonic development. Our results collectively indicate that in vitro and in vivo exposure to concentrations of DHLA higher than 50 μM DHLA induces apoptosis and retards early pre- and post-implantation development,and support the potential of DHLA to induce embryonic cytotoxicity. View Publication -
Chang K-A et al. ( 2012) Neurochemistry international 61 6 885--891Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer's disease.
Recent studies have proposed that chronic treatment with antidepressants increases neurogenesis in the adult hippocampus. However,the effect of antidepressants on fetal neural stem cells (NSCs) has not been well defined. Our study shows the dose-dependent effects of fluoxetine on the proliferation and neural differentiation of NSCs. Fluoxetine,even at nanomolar concentrations,stimulated proliferation of NSCs and increased the number of βIII-tubulin (Tuj 1)- and neural nucleus marker (NeuN)-positive cells,but not glial fibrillary acidic protein (GFAP)-positive cells. These results suggest that fluoxetine can enhance neuronal differentiation. In addition,fluoxetine has protective effects against cell death induced by oligomeric amyloid beta (Aβ(42)) peptides. Taken together,these results clearly show that fluoxetine promotes both the proliferation and neuronal differentiation of NSCs and exerts protective effects against Aβ(42)-induced cytotoxicities in NSCs,which suggest that the use of fluoxetine is applicable for cell therapy for various neurodegenerative diseases,such as Alzheimer's and Parkinson's diseases by its actions in NSCs. View Publication -
Johnson K et al. (MAY 2012) Science 336 6082 717--21A stem cell-based approach to cartilage repair.
Osteoarthritis (OA) is a degenerative joint disease that involves the destruction of articular cartilage and eventually leads to disability. Molecules that promote the selective differentiation of multipotent mesenchymal stem cells (MSCs) into chondrocytes may stimulate the repair of damaged cartilage. Using an image-based high-throughput screen,we identified the small molecule kartogenin,which promotes chondrocyte differentiation (median effective concentration = 100 nM),shows chondroprotective effects in vitro,and is efficacious in two OA animal models. Kartogenin binds filamin A,disrupts its interaction with the transcription factor core-binding factor β subunit (CBFβ),and induces chondrogenesis by regulating the CBFβ-RUNX1 transcriptional program. This work provides new insights into the control of chondrogenesis that may ultimately lead to a stem cell-based therapy for osteoarthritis. View Publication -
Bé et al. (MAR 2013) European biophysics journal : EBJ 42 2-3 159--68Dihydrolipoic acid reduces cytochrome b561 proteins.
Cytochrome b561 (Cyt-b561) proteins constitute a family of trans-membrane proteins that are present in a wide variety of organisms. Two of their characteristic properties are the reducibility by ascorbate (ASC) and the presence of two distinct b-type hemes localized on two opposite sides of the membrane. Here we show that the tonoplast-localized and the putative tumor suppressor Cyt-b561 proteins can be reduced by other reductants than ASC and dithionite. A detailed spectral analysis of the ASC-dependent and dihydrolipoic acid (DHLA)-dependent reduction of these two Cyt-b561 proteins is also presented. Our results are discussed in relation to the known antioxidant capability of DHLA as well as its role in the regeneration of other antioxidant compounds of cells. These results allow us to speculate on new biological functions for the trans-membrane Cyt-b561 proteins. View Publication -
Jeerage KM et al. (OCT 2012) Neurotoxicology 33 5 1170--9Neurite outgrowth and differentiation of rat cortex progenitor cells are sensitive to lithium chloride at non-cytotoxic exposures.
Neuron-specific in vitro screening strategies have the potential to accelerate the evaluation of chemicals for neurotoxicity. We examined neurite outgrowth as a measure of neuronal response with a commercially available rat cortex progenitor cell model,where cells were exposed to a chemical during a period of cell differentiation. In control cultures,the fraction of beta-III-tubulin positive neurons and their neurite length increased significantly with time,indicating differentiation of the progenitor cells. Expression of glial fibrillary acidic protein,an astrocyte marker,also increased significantly with time. By seeding progenitor cells at varying densities,we demonstrated that neurite length was influenced by cell-cell spacing. After ten days,cultures seeded at densities of 1000 cells/mm(2) or lower had significantly shorter neurites than cultures seeded at densities of 1250 cells/mm(2) or higher. Progenitor cells were exposed to lithium,a neuroactive chemical with diverse modes of action. Cultures exposed to 30 mmol/L or 10 mmol/L lithium chloride (LiCl) had significantly lower metabolic activity than control cultures,as reported by adenosine triphosphate content,and no neurons were observed after ten days of exposure. Cultures exposed to 3 mmol/L,1 mmol/L,or 0.3 mmol/L LiCl,which encompass lithium's therapeutic range,had metabolic activity similar to control cultures. These cultures exhibited concentration-dependent decreases in neurite outgrowth after ten days of LiCl exposure. Neurite outgrowth results were relatively robust,regardless of the evaluation methodology. This work demonstrates that measurement of neurite outgrowth in differentiating progenitor cell cultures can be a sensitive endpoint for neuronal response under non-cytotoxic exposure conditions. View Publication -
Goustard-Langelier B et al. (JAN 2013) The Journal of nutritional biochemistry 24 1 380--7Rat neural stem cell proliferation and differentiation are durably altered by the in utero polyunsaturated fatty acid supply.
We isolated neural stem cells/neural progenitors (NSC) from 1-day-old rat pups born to mothers fed diets that were deficient or supplemented with n-3 polyunsaturated fatty acids (PUFAs) and compared their proliferation and differentiation in vitro. The cells isolated from the n-3PUFA-deficient pups consistently proliferated more slowly than cells that were isolated from n-3PUFA-supplemented pups,despite the fact that both were cultured under the same conditions. The differences in the proliferation rates were evaluated up until 40 days of culture and were highly significant. When the cells were allowed to differentiate,the deficient cells exhibited a higher degree of neuronal maturation in response to the addition of PUFAs in the medium,as demonstrated by an increase in neurite length,whereas the neurons derived from the supplemented pups showed no change. This result was consistent,regardless of the age of the culture. The properties of the NSC were durably modified throughout the length of the culture,although the membrane phospholipid compositions were similar. We examined the differential expression of selected mRNAs and micro RNAs. We found significant differences in the gene expression of proliferating and differentiating cells,and a group of genes involved in neurogenesis was specifically modified by n-3 PUFA treatment. We conclude that n-3 PUFA levels in the maternal diet can induce persistent modifications of the proliferation and differentiation of NSCs and of their transcriptome. Therefore,the n-3 supply received in utero may condition on a long-term basis cell renewal in the brain. View Publication -
Huan J et al. (JAN 2013) Cancer research 73 2 918--29RNA trafficking by acute myelogenous leukemia exosomes.
Extrinsic signaling cues in the microenvironment of acute myelogenous leukemia (AML) contribute to disease progression and therapy resistance. Yet,it remains unknown how the bone marrow niche in which AML arises is subverted to support leukemic persistence at the expense of homeostatic function. Exosomes are cell membrane-derived vesicles carrying protein and RNA cargoes that have emerged as mediators of cell-cell communication. In this study,we examined the role of exosomes in developing the AML niche of the bone marrow microenvironment,investigating their biogenesis with a focus on RNA trafficking. We found that both primary AML and AML cell lines released exosome-sized vesicles that entered bystander cells. These exosomes were enriched for several coding and noncoding RNAs relevant to AML pathogenesis. Furthermore,their uptake by bone marrow stromal cells altered their secretion of growth factors. Proof-of-concept studies provided additional evidence for the canonical functions of the transferred RNA. Taken together,our findings revealed that AML exosome trafficking alters the proliferative,angiogenic,and migratory responses of cocultured stromal and hematopoietic progenitor cell lines,helping explain how the microenvironmental niche becomes reprogrammed during invasion of the bone marrow by AML. View Publication -
Yoshida T et al. ( 2012) Oncotarget 3 12 1533--1545Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
A small molecule compound,JTP-74057/GSK1120212/trametinib,had been discovered as a very potent antiproliferative agent able to induce the accumulation of CDK inhibitor p15INK4b. To conduct its drug development rationally as an anticancer agent,molecular targets of this compound were identified as MEK1/2 using compound-affinity chromatography. It was shown that JTP-74057 directly bound to MEK1 and MEK2 and allosterically inhibited their kinase activities,and that its inhibitory characteristics were similar to those of the known and different chemotype of MEK inhibitors PD0325901 and U0126. It was further shown that JTP-74057 induced rapid and sustained dephosphorylation of phosphorylated MEK in HT-29 colon and other cancer cell lines,while this decrease in phosphorylated MEK was not observed in PD0325901-treated cancer cells. Physicochemical analyses revealed that JTP-74057 preferentially binds to unphosphorylated MEK (u-MEK) in unique characteristics of both high affinity based on extremely low dissociation rates and ability stabilizing u-MEK with high thermal shift,which were markedly different from PD0325901. These findings indicate that JTP-74057 is a novel MEK inhibitor able to sustain MEK to be an unphosphorylated form resulting in pronounced suppression of the downstream signaling pathways involved in cellular proliferation. View Publication -
Cuddihy MJ et al. (APR 2013) Small (Weinheim an der Bergstrasse,Germany) 9 7 1008--15Replication of bone marrow differentiation niche: comparative evaluation of different three-dimensional matrices.
The comparative evaluation of different 3D matrices-Matrigel,Puramatrix,and inverted colloidal crystal (ICC) scaffolds-provides a perspective for studying the pathology and potential cures for many blood and bone marrow diseases,and further proves the significance of 3D cultures with direct cell-cell contacts for in vitro mimicry of the human stem cell niche. View Publication -
Madaan A et al. (MAR 2013) International immunopharmacology 15 3 606--13Anti-inflammatory activity of a naphthyridine derivative (7-chloro-6-fluoro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide) possessing in vitro anticancer potential.
We have previously synthesized a series of 1,8-naphthyridine-3-carboxamide derivatives to identify potential anti-cancer/anti-inflammatory compounds. Three derivatives,7-chloro-N-(3-(cyclopentylamino)-3-oxo-1-phenylpropyl)-6-fluoro-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide (C-22),7-chloro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide (C-31) and 7-chloro-6-fluoro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide (C-34) demonstrated high cytotoxicity against a number of cancer cell lines and inhibited secretion of IL-1-β and IL-6. In the present study,C-22,C-31 and C-34 were assessed for modulation of pro-inflammatory cytokines,TNF-α and IL-8,chemokine RANTES and NO produced by lipopolysaccharide (LPS)-treated mouse Dendritic cells (DCs). Among the 3 compounds,C-34 showed the most potent inhibition of inflammatory markers in DC model at 0.2 and 2 μM. C-34 also significantly downregulated the secretion of TNF-α,IL-1-β and IL-6 by murine splenocytes and THP-1 cells against LPS induced levels. In vitro effects of C-34 on bone marrow toxicity were assessed in CFU-GM assay. Human CFU-GM population was comparatively more sensitive to C-34 (0.1-10 μM) than murine CFU-GM. IC50 values for murine and human CFU-GM were not attained. C-34 was further examined for in vivo suppression of LPS induced cytokines in a mice model. At doses ranging from 1.25 to 5 mg/kg,C-34 led to significant inhibition of TNF-α,IL-1-β,IL-6 and MIP-1-α. At the highest dose of 5 mg/kg,C-34 also protected LPS-treated mice against endotoxin-induced lethality. In conclusion,C-34 demonstrates anti-inflammatory activity in vitro and in vivo in addition to cytotoxic properties. This finding suggests its potential for further development as a synthetic naphthyridine derivative with dual anti-cancer and anti-inflammatory (cytokine inhibition) properties. View Publication -
Cary RL et al. (JUL 2013) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28 7 1599--610Inhibition of Ca²�?�/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation.
Bone remodeling,a physiological process characterized by bone formation by osteoblasts (OBs) and resorption of preexisting bone matrix by osteoclasts (OCs),is vital for the maintenance of healthy bone tissue in adult humans. Imbalances in this vital process result in pathological conditions including osteoporosis. Owing to its initial asymptomatic nature,osteoporosis is often detected only after the patient has sustained significant bone loss or a fracture. Hence,anabolic therapeutics that stimulate bone accrual is in high clinical demand. Here we identify Ca²?/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) as a potential target for such therapeutics because its inhibition enhances OB differentiation and bone growth and suppresses OC differentiation. Mice null for CaMKK2 possess higher trabecular bone mass in their long bones,along with significantly more OBs and fewer multinuclear OCs. In vitro,although Camkk2?/? mesenchymal stem cells (MSCs) yield significantly higher numbers of OBs,bone marrow cells from Camkk2?/? mice produce fewer multinuclear OCs. Acute inhibition of CaMKK2 by its selective,cell-permeable pharmacological inhibitor STO-609 also results in increased OB and diminished OC formation. Further,we find phospho-protein kinase A (PKA) and Ser¹³³ phosphorylated form of cyclic adenosine monophosphate (cAMP) response element binding protein (pCREB) to be markedly elevated in OB progenitors deficient in CaMKK2. On the other hand,genetic ablation of CaMKK2 or its pharmacological inhibition in OC progenitors results in reduced pCREB as well as significantly reduced levels of its transcriptional target,nuclear factor of activated T cells,cytoplasmic (NFATc1). Moreover,in vivo administration of STO-609 results in increased OBs and diminished OCs,conferring significant protection from ovariectomy (OVX)-induced osteoporosis in adult mice. Overall,our findings reveal a novel function for CaMKK2 in bone remodeling and highlight the potential for its therapeutic inhibition as a valuable bone anabolic strategy that also inhibits OC differentiation in the treatment of osteoporosis. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 70 项目
- HLA 52 项目
- 上皮细胞生物学 269 项目
- 免疫 1012 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 48 项目
- 嵌合体 25 项目
- 干细胞生物学 2827 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 7 项目
- 新陈代谢 7 项目
- 杂交瘤制备 2 项目
- 疾病建模 248 项目
- 癌症 6 项目
- 神经科学 650 项目
- 移植研究 100 项目
- 类器官 178 项目
- 细胞外囊泡研究 10 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 113 项目
- 细胞系制备 191 项目
- 脐带血库 64 项目
- 血管生成细胞研究 1 项目
- 传染病 64 项目
- 内皮细胞生物学 7 项目
- 杂交瘤生成 14 项目
- 癌症研究 724 项目
- 血管生成细胞研究 51 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 11 项目
- CellShield 1 项目
- CellSTACK 1 项目
- DermaCult 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ES-Cult 78 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- Maestro 2 项目
- Matrigel 2 项目
- MegaCult 37 项目
- STEMprep 11 项目
- ALDEFLUOR 237 项目
- AggreWell 82 项目
- ArciTect 38 项目
- BloodStor 2 项目
- BrainPhys 84 项目
- CellAdhere 3 项目
- ClonaCell 107 项目
- CloneR 9 项目
- CryoStor 75 项目
- EC-Cult 1 项目
- EasySep 963 项目
- EpiCult 15 项目
- HemaTox 4 项目
- HepatiCult 32 项目
- Hypothermosol 1 项目
- ImmunoCult 39 项目
- IntestiCult 213 项目
- Lymphoprep 12 项目
- MammoCult 45 项目
- MesenCult 164 项目
- MethoCult 499 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 373 项目
- NeuroFluor 3 项目
- PBS-MINI 8 项目
- PancreaCult 11 项目
- PneumaCult 119 项目
- RSeT 13 项目
- ReLeSR 10 项目
- RoboSep 43 项目
- RosetteSep 268 项目
- STEMdiff 193 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 38 项目
- SmartDish 1 项目
- StemSpan 251 项目
- TeSR 1545 项目
- ThawSTAR 5 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 229 项目
- CD4+ 46 项目
- CD8+ 29 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 162 项目
- PSC衍生 37 项目
- T 细胞 441 项目
- 上皮细胞 143 项目
- 中胚层 5 项目
- 乳腺细胞 95 项目
- 先天性淋巴细胞 32 项目
- 全血 10 项目
- 其他子集 1 项目
- 其他细胞系 10 项目
- 内皮细胞 11 项目
- 内胚层 4 项目
- 前列腺细胞 18 项目
- 单个核细胞 93 项目
- 单核细胞 178 项目
- 多能干细胞 1986 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 21 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 92 项目
- 树突状细胞(DCs) 118 项目
- 气道细胞 4 项目
- 淋巴细胞 73 项目
- 癌细胞及细胞系 149 项目
- 癌细胞和细胞系 1 项目
- 白细胞 24 项目
- 白细胞单采样本 13 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 465 项目
- 神经细胞 12 项目
- 粒细胞及其亚群 96 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 40 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 27 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血浆 3 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 调节性细胞 10 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 968 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 25 项目
- 间充质干/祖细胞 188 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 3 项目
- 骨髓基质细胞 1 项目
- 骨髓间质细胞 2 项目
- 髓系细胞 135 项目
- 肾脏细胞 8 项目
- CD4+T细胞 100 项目
- CD8+T细胞 86 项目
- PSC衍生上皮细胞 39 项目
- PSC衍生中胚层 25 项目
- PSC衍生内皮细胞 20 项目
- PSC衍生内胚层 28 项目
- PSC衍生心肌细胞 26 项目
- PSC衍生神经细胞 130 项目
- PSC衍生肝细胞 18 项目
- PSC衍生造血干细胞 39 项目
- PSC衍生间充质细胞 27 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 96 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 17 项目
- 神经元 201 项目
- 调节性T细胞 59 项目
- 骨髓瘤 5 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号